I hate to say it, but think we have all just been

I hate to say it, but think we have all just been shot in the foot. To file a preliminary R/S with supposed gold pours coming next month, makes absolutely no sense, if you aren’t planning to use it very soon. I think we can kiss any significant pop on good news goodbye. The average Joe shareholder is not going to buy many shares with a R/S looming overhead, whether they produce gold or not. It’s just not a good trading strategy.
I know I sure wouldn’t. I hope I’m wrong.
I have yet to see a R/S work in favor of common shareholders and I’ve seen quite a few. Usually dilution starts immediately, as CEO’s start issuing new shares to acquire new financing, and most traders are aware of that. My opinion only, but I’m guessing that’s what this is about, because Mexus is heavily dependent on shareholder loans and 3rd party notes, the next one being for roughly 100K due in Aug, with another due in Dec. In other words, the well is almost dry, and that takes on even more significance if production is lower than expected from the first batch of pregnant pond solution processing.
Mexus is already on the pink sheets, so trying to maintain their former higher OTC tier doesn’t hold water. They could uplist at any time once their pps goes higher for a period of time.
Am I against a R/S? No, sometimes they are necessary, but it would have been more fair to shareholders, and smarter to wait til after production started, get a potential pop on good results and allow long time shareholders to reap some rewards for their loyalty, then to slam them with a Pre- R/S filing as things are just beginning to look up. They could wait a few months and as production allows, then do a split, if necessary. That’s why I believe it’s coming sooner, rather than later. More than likely a minimum of 1-for-10 is my guess. Once the waiting period of the Pre-14C expires the R/S can happen anytime with very little warning, as it often does.

“A reverse stock split of all outstanding shares of the Company’s common stock, par value $0.001 per share, at a ratio of not less than 1-for-2 and not greater than 1-for-20, such ratio to be determined by the Company’s Board at any time before March 30, 2022, without further approval or authorization of our stockholders (the “Reverse Split”).”